Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

被引：15
|
作者：
Liu, Shangde [1 ]
Li, Shanshan [1 ]
Yuan, Duo [1 ]
Wang, Enmao [1 ]
Xie, Roujie [1 ]
Zhang, Weiqi [1 ]
Kong, Yi [2 ]
Zhu, Xiong [1 ]
机构：
[1] China Pharmaceut Univ, Inst Med & Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Life & Technol, Nanjing 210009, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 209卷
关键词：
PAR4; Small-molecule antagonists; Antiplatelet agents; SAR; Structural optimization; BMS-986120; BMS-986141; Preclinical trials; Clinical trials; ACUTE CORONARY SYNDROMES; THROMBIN-RECEPTOR; PLATELET ACTIVATION; THROMBOXANE PRODUCTION; IN-VITRO; INHIBITION; YD-3; AGGREGATION; DISCOVERY; PEPTIDES;
D O I：
10.1016/j.ejmech.2020.112893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protease activated receptor 4 (PAR4) is a key target in antiplatelet medication to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth while retaining initial thrombus formation by acting on the late diffusion stage of platelet activation, which may provide a safer alternative than other antiplatelet agents. Currently, research on PAR4 antagonists is of increasing interest in the field of antiplatelet agents. This article provides an overview of the discovery and development of small-molecule antagonists of PAR4 as novel antiplatelet agents, including structure-activity relationship (SAR) analysis, progress of structure and bioassay optimization, and the latest structural and/or clinical information of representative small-molecule antagonists of PAR4. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：15
相关论文
共 30 条
  • [21] Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2
    Zhang, Yong
    Yu, Guoyu
    Wang, Yanjie
    Xiang, Yang
    Gao, Qian
    Jiang, Ping
    Zhang, Jie
    Lee, Wenhui
    Zhang, Yun
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (22) : 3771 - 3780
  • [22] Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets
    Young, Summer E.
    Duvernay, Matthew T.
    Schulte, Michael L.
    Lindsley, Craig W.
    Hamm, Heidi E.
    PLOS ONE, 2013, 8 (06):
  • [23] Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR1 and PAR4 in platelets
    Navarro-Nunez, L.
    Rivera, J.
    Guerrero, J. A.
    Martinez, C.
    Vicente, V.
    Lozano, M. L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (06) : 1548 - 1556
  • [24] Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca2+ mobilization and ERK phosphorylation in healthy Japanese subjects
    Morikawa, Yoichiro
    Kato, Hisashi
    Kashiwagi, Hirokazu
    Nishiura, Nobuko
    Akuta, Keigo
    Honda, Shigenori
    Kanakura, Yuzuru
    Tomiyama, Yoshiaki
    THROMBOSIS RESEARCH, 2018, 162 : 44 - 52
  • [25] Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists
    Cho, Nam-Chul
    Cha, Ji Hyoun
    Kim, Hyojin
    Kwak, Jinsook
    Kim, Dohee
    Seo, Seung-Hwan
    Shin, Ji-Sun
    Kim, TaeHun
    Park, Ki Duk
    Lee, Jiyoun
    No, Kyoung Tai
    Kim, Yun Kyung
    Lee, Kyung-Tae
    Pae, Ae Nim
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (24) : 7717 - 7727
  • [26] Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?
    Fender, Anke C.
    Rauch, Bernhard H.
    Geisler, Tobias
    Schroer, Karsten
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (11) : 2013 - 2025
  • [27] Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin
    Temple, Kayla J.
    Duvernay, Matthew T.
    Young, Summer E.
    Wen, Wandong
    Wu, Wenjun
    Maeng, Jae G.
    Blobaum, Anna L.
    Stauffer, Shaun R.
    Hamm, Heidi E.
    Lindsley, Craig W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (16) : 7690 - 7695
  • [28] Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability
    Li, Shanshan
    Liu, Shangde
    Yuan, Duo
    Liu, Renjie
    Hu, Lifang
    Zhu, Xiong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 280
  • [29] Novel serotonin 5-HT2A receptor antagonists derived from 4-phenylcyclohexane-5-spiro-and 5-methyl-5-phenyl-hydantoin, for use as potential antiplatelet agents
    Anna Czopek
    Monika Kubacka
    Adam Bucki
    Agata Siwek
    Barbara Filipek
    Maciej Pawłowski
    Marcin Kołaczkowski
    Pharmacological Reports, 2021, 73 : 1361 - 1372
  • [30] Novel serotonin 5-HT2A receptor antagonists derived from 4-phenylcyclohexane-5-spiro-and 5-methyl-5-phenyl-hydantoin, for use as potential antiplatelet agents
    Czopek, Anna
    Kubacka, Monika
    Bucki, Adam
    Siwek, Agata
    Filipek, Barbara
    Pawlowski, Maciej
    Kolaczkowski, Marcin
    PHARMACOLOGICAL REPORTS, 2021, 73 (05) : 1361 - 1372
123